Minerva Neurosciences Inc. (NASDAQ:NERV) traded up 1.7% during trading on Friday . The stock traded as high as $10.65 and last traded at $10.45, with a volume of 87,591 shares. The stock had previously closed at $10.28.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Wednesday. Jefferies Group reissued a “buy” rating and set a $17.00 target price on shares of Minerva Neurosciences in a report on Wednesday, June 8th. Finally, JMP Securities boosted their target price on Minerva Neurosciences from $10.00 to $17.00 in a report on Thursday, May 26th.

The company’s market cap is $292.27 million. The stock’s 50-day moving average is $10.91 and its 200-day moving average is $6.91.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. Equities analysts forecast that Minerva Neurosciences Inc. will post ($1.05) EPS for the current fiscal year.

In other Minerva Neurosciences news, Director David Kupfer bought 55,635 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were acquired at an average price of $10.84 per share, with a total value of $603,083.40. Following the completion of the purchase, the director now directly owns 209,188 shares in the company, valued at approximately $2,267,597.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.